Aellig W H, Nüesch E, Engel G, Grevel J, Niederberger W, Rosenthaler J
Br J Clin Pharmacol. 1986 Jan;21(1):45-51. doi: 10.1111/j.1365-2125.1986.tb02821.x.
Bopindolol, an esterified beta-adrenoceptor blocking drug, was administered to nine healthy male volunteers in oral (1 mg and 4 mg) and intravenous (1 mg) doses. Plasma concentrations determined using a radio-receptor assay (RRA) and high pressure liquid chromatography (h.p.l.c.) yielded almost identical results, indicating that hydrolysed bopindolol, the major metabolite, is responsible for the pharmacological activity of the drug. After intravenous administration the half-life for the formation of the hydrolysis product was about 0.3 h. The elimination of hydrolysed bopindolol from the plasma, determined with a one-compartment model occurred with a half-life of about 4 h. There were indications for a longer beta phase of elimination with a half-life of about 8 h, which, owing to the relative insensitivity of the method for concentrations present after more than 24 h, could not be determined exactly. The absolute bioavailability of the active compound is about 70%. Cardiac beta-adrenoceptor blockade was determined as the reduction in exercise-induced tachycardia. With oral doses the maximum effect was reached after 3 h (-29 beats min-1 after 1 mg, -40 beats min-1 after 4 mg). After intravenous administration most of the effect was present after 0.5 h but the maximum effect (-33 beats min-1) was only reached at 3 h. Bopindolol possesses a long duration of action: after 48 h 33% of the maximum effect of the oral dose of 4 mg was still present.(ABSTRACT TRUNCATED AT 250 WORDS)
波吲洛尔是一种酯化的β肾上腺素受体阻断药,以口服(1毫克和4毫克)和静脉注射(1毫克)剂量给予9名健康男性志愿者。使用放射受体分析法(RRA)和高压液相色谱法(h.p.l.c.)测定的血浆浓度得出几乎相同的结果,表明主要代谢产物水解波吲洛尔是该药物药理活性的原因。静脉注射后,水解产物形成的半衰期约为0.3小时。用单室模型测定,水解波吲洛尔从血浆中的消除半衰期约为4小时。有迹象表明消除的β相更长,半衰期约为8小时,但由于该方法对24小时后存在的浓度相对不敏感,无法准确测定。活性化合物的绝对生物利用度约为70%。心脏β肾上腺素受体阻滞通过运动诱发心动过速的降低来测定。口服给药后,3小时达到最大效应(1毫克后为-29次/分钟,4毫克后为-40次/分钟)。静脉注射后,大部分效应在0.5小时后出现,但最大效应(-33次/分钟)仅在3小时达到。波吲洛尔作用持续时间长:48小时后,4毫克口服剂量最大效应的33%仍然存在。(摘要截短于250字)